HRMY
Harmony Biosciences Holdings, Inc. NASDAQ Listed Aug 19, 2020$33.28
-1.45%
vs $33.77
Mkt Cap $1.9B
52w Low $25.90
50.5% of range
52w High $40.51
50d MA $31.46
200d MA $32.29
P/E (TTM)
12.3x
EV/EBITDA
5.2x
P/B
2.2x
Debt/Equity
0.3x
ROE
18.2%
P/FCF
5.6x
RSI (14)
59.00
ATR (14)
$1.14
Beta
0.89
50d MA
$31.46
200d MA
$32.29
Avg Volume
820.6K
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
630 West Germantown Pike · Plymouth Meeting, PA 19462 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 32.78 | -11.7% | -4.1% | -1.4% | -2.6% | -0.1% | +2.3% | — |
| Feb 24, 2026 | AMC | 0.84 | 0.38 | -54.8% | 28.19 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% | — |
| Nov 4, 2025 | AMC | 0.92 | 0.87 | -5.4% | 30.72 | -1.3% | +2.1% | -1.3% | +1.6% | +1.2% | +3.6% | — |
| Aug 5, 2025 | AMC | 0.78 | 0.68 | -12.8% | 34.94 | +0.8% | -0.8% | -1.4% | +0.0% | +1.8% | +1.9% | — |
| May 6, 2025 | AMC | 0.59 | 0.78 | +32.2% | 32.05 | +0.5% | +4.3% | +1.9% | -0.1% | +4.7% | -3.6% | — |
| Feb 25, 2025 | AMC | 0.74 | 0.85 | +14.9% | 36.97 | -2.5% | -9.5% | -2.2% | +3.4% | -4.9% | +1.3% | — |
| Oct 29, 2024 | AMC | 0.67 | 0.79 | +17.9% | 41.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% | — |
| Aug 6, 2024 | AMC | -0.06 | 0.20 | +433.3% | 32.83 | +0.9% | +2.2% | +1.3% | -0.4% | -1.3% | +5.0% | — |
| Apr 30, 2024 | AMC | 0.60 | 0.67 | +11.7% | 30.91 | -1.6% | -2.1% | +4.7% | -0.4% | -2.1% | +1.5% | — |
| Feb 22, 2024 | AMC | 0.48 | 0.45 | -6.2% | 31.45 | -1.1% | +3.3% | -0.1% | +3.1% | -0.7% | -3.5% | — |
| Oct 31, 2023 | AMC | 0.65 | 0.75 | +15.4% | 23.54 | +1.6% | +4.2% | +0.4% | +5.2% | -3.8% | -2.3% | — |
| Aug 1, 2023 | AMC | 0.63 | 0.56 | -11.1% | 33.99 | -0.9% | -4.2% | +0.0% | +3.2% | -0.3% | -0.6% | — |
| May 2, 2023 | AMC | 0.44 | 0.48 | +9.1% | 33.55 | +4.5% | +7.3% | -1.2% | +0.9% | +0.5% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | UBS | Maintains | Neutral → Neutral | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 25 | BofA Securities | Maintains | Underperform → Underperform | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | -1.8% | +1.3% | -2.2% |
| Feb 11 | UBS | Downgrade | Buy → Neutral | — | $37.93 | $37.08 | -2.2% | -3.5% | -2.0% | +0.4% | +2.5% | -4.4% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $37.55 | $37.55 | +0.0% | +0.9% | +1.8% | -0.7% | -6.6% | +0.8% |
| Dec 1 | Mizuho | Maintains | Outperform → Outperform | — | $35.29 | $35.60 | +0.9% | +0.6% | +1.4% | +2.7% | +3.4% | +4.1% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.31 | $34.50 | +0.6% | +2.8% | +0.2% | +0.6% | -0.8% | +0.6% |
| Nov 24 | Needham | Maintains | Buy → Buy | — | $34.31 | $34.50 | +0.6% | +2.8% | +0.2% | +0.6% | -0.8% | +0.6% |
| Nov 6 | Mizuho | Maintains | Outperform → Outperform | — | $31.35 | $31.50 | +0.5% | -1.3% | +1.6% | +1.2% | +3.6% | +1.7% |
| Oct 15 | UBS | Maintains | Buy → Buy | — | $26.84 | $26.67 | -0.6% | -0.8% | -2.6% | -0.2% | +0.5% | +0.5% |
| Sep 25 | Mizuho | Maintains | Outperform → Outperform | — | $26.76 | $26.71 | -0.2% | +1.0% | +1.7% | +0.5% | -0.3% | -2.3% |
| Sep 25 | Deutsche Bank | Maintains | Buy → Buy | — | $26.76 | $26.71 | -0.2% | +1.0% | +1.7% | +0.5% | -0.3% | -2.3% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.76 | $26.71 | -0.2% | +1.0% | +1.7% | +0.5% | -0.3% | -2.3% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | $32.07 | $29.92 | -6.7% | -16.6% | +1.0% | +1.7% | +0.5% | -0.3% |
| Jul 10 | Deutsche Bank | Maintains | Buy → Buy | — | $34.29 | $34.35 | +0.2% | +0.1% | -1.0% | +2.1% | +0.4% | +1.1% |
| May 15 | Mizuho | Maintains | Outperform → Outperform | — | $33.39 | $33.64 | +0.7% | +2.5% | +2.5% | +2.4% | -0.8% | -3.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $32.05 | $32.20 | +0.5% | +4.3% | +1.9% | -0.1% | +4.7% | -3.6% |
| May 6 | Needham | Maintains | Buy → Buy | — | $29.96 | $31.11 | +3.8% | +7.0% | +4.3% | +1.9% | -0.1% | +4.7% |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $29.61 | $29.58 | -0.1% | -0.8% | +0.3% | +0.1% | +1.3% | +1.5% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $29.07 | $29.00 | -0.2% | -0.3% | +0.6% | +1.2% | -2.6% | -2.8% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.40 | $29.31 | +3.2% | -1.0% | +3.3% | -0.3% | +0.6% | +1.2% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $28.40 | $29.31 | +3.2% | -1.0% | +3.3% | -0.3% | +0.6% | +1.2% |
| Mar 18 | Mizuho | Maintains | Outperform → Outperform | — | $34.32 | $34.32 | +0.0% | +1.3% | -1.1% | +1.5% | +1.1% | -2.9% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.47 | $33.55 | +0.2% | -2.2% | +3.4% | -4.9% | +1.3% | +3.5% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $36.97 | $36.03 | -2.5% | -9.5% | -2.2% | +3.4% | -4.9% | +1.3% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $34.18 | $34.63 | +1.3% | +8.2% | -9.5% | -2.2% | +3.4% | -4.9% |
| Feb 20 | Mizuho | Maintains | Outperform → Outperform | — | $35.32 | $35.15 | -0.5% | -1.2% | -0.9% | -1.1% | +8.2% | -9.5% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.09 | $36.82 | -5.8% | -9.6% | -1.2% | -0.9% | -1.1% | +8.2% |
| Feb 19 | Needham | Maintains | Buy → Buy | — | $39.09 | $36.82 | -5.8% | -9.6% | -1.2% | -0.9% | -1.1% | +8.2% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.01 | $38.03 | +0.1% | +0.6% | +0.4% | +1.0% | +1.9% | -1.9% |
| Jan 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.93 | $36.93 | +0.0% | +4.4% | +1.3% | +3.6% | -4.4% | -1.7% |
| Jan 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $33.86 | $35.42 | +4.6% | +7.6% | -0.1% | +1.4% | +4.4% | +1.3% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $33.86 | $35.42 | +4.6% | +7.6% | -0.1% | +1.4% | +4.4% | +1.3% |
| Oct 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.49 | $37.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% |
| Oct 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $41.49 | $37.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% |
| Oct 30 | Needham | Maintains | Buy → Buy | — | $41.49 | $37.49 | -9.6% | -18.5% | -4.9% | +3.0% | -0.1% | +1.1% |
| Oct 29 | Needham | Maintains | Buy → Buy | — | $35.75 | $37.58 | +5.1% | +16.1% | -18.5% | -4.9% | +3.0% | -0.1% |
| Oct 10 | Mizuho | Maintains | Outperform → Outperform | — | $33.60 | $34.00 | +1.2% | +3.6% | +0.1% | +1.9% | +0.1% | -1.9% |
| Oct 2 | Needham | Maintains | Buy → Buy | — | $39.24 | $39.22 | -0.1% | -9.4% | -2.2% | -0.5% | -0.6% | +1.1% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | $38.25 | $38.31 | +0.2% | -1.1% | -1.4% | +6.7% | -1.7% | +2.2% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $37.28 | $37.60 | +0.9% | +1.3% | +3.0% | -0.4% | +0.1% | -1.2% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $33.55 | $34.00 | +1.3% | +1.3% | -0.4% | -1.3% | +5.0% | -1.8% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $30.92 | $32.00 | +3.5% | +6.2% | +2.2% | +1.3% | -0.4% | -1.3% |
| Jun 25 | Needham | Maintains | Buy → Buy | — | $30.10 | $30.01 | -0.3% | -0.1% | +3.3% | +1.3% | -4.2% | +0.8% |
| Jun 24 | Needham | Maintains | Buy → Buy | — | $30.13 | $30.28 | +0.5% | -0.1% | -0.1% | +3.3% | +1.3% | -4.2% |
| May 1 | Needham | Maintains | Buy → Buy | — | $30.91 | $30.42 | -1.6% | -2.1% | +4.7% | -0.4% | -2.1% | +1.5% |
| Apr 30 | Needham | Maintains | Buy → Buy | — | $29.25 | $31.65 | +8.2% | +5.7% | -2.1% | +4.7% | -0.4% | -2.1% |
| Apr 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.26 | $31.40 | +0.4% | -5.6% | +0.1% | +0.9% | -2.0% | -0.5% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $29.37 | $30.01 | +2.2% | +6.4% | -5.6% | +0.1% | +0.9% | -2.0% |
No insider trades available.
8-K · 2.02
!! High
Harmony Biosciences Holdings, Inc. -- 8-K 2.02: Earnings Results
Harmony Biosciences reported quarterly earnings results; investors should review the attached press release for specific financial performance metrics and guidance updates.
May 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Harmony's leadership transition to a new CFO could signal strategic shifts in financial management and capital allocation, potentially affecting investor confidence and operational direction.
Apr 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Leadership transitions at Harmony create execution risk and potential disruption, requiring investors to assess whether new management can maintain operational momentum and shareholder value.
Apr 2
8-K
Harmony Biosciences Holdings, Inc. -- 8-K Filing
I cannot provide a meaningful analysis as the summary lacks substantive information about the actual business event or transaction disclosed in this 8-K filing.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 3,157,639 | $88M | Added | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 2,714,353 | $76M | New | Mar 2026 |
| 3 | Morgan Stanley | 1,635,014 | $61M | Reduced | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 2,102,315 | $59M | New | Mar 2026 |
| 5 | Sg Americas Securities, Llc | 2,018,174 | $57M | Added | Mar 2026 |
| 6 | Arrowstreet Capital, Limited Partnership | 1,382,113 | $39M | Reduced | Mar 2026 |
| 7 | Renaissance Technologies Llc | 1,077,371 | $30M | Added | Mar 2026 |
| 8 | Millennium Management | 954,359 | $27M | Added | Mar 2026 |
| 9 | Jpmorgan Chase & Co | 823,513 | $22M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 733,443 | $21M | Added | Mar 2026 |
| 11 | Aqr Capital Management Llc | 716,246 | $20M | Reduced | Mar 2026 |
| 12 | Invesco Ltd. | 628,247 | $18M | Added | Mar 2026 |
| 13 | Citadel Advisors Llc | 585,623 | $16M | Added | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 545,188 | $15M | Added | Mar 2026 |
| 15 | Nomura Holdings Inc | 520,947 | $15M | Added | Mar 2026 |
| 16 | Man Group Plc | 461,898 | $13M | Added | Mar 2026 |
| 17 | Ubs Group Ag | 447,991 | $13M | Added | Mar 2026 |
| 18 | Northern Trust Corp | 423,229 | $12M | Added | Mar 2026 |
| 19 | Tang Capital Management Llc | 290,292 | $11M | Added | Dec 2025 |
| 20 | Qube Research & Technologies Ltd | 352,637 | $10M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.95B
Enterprise Value
$1.32B
P/E (TTM)
12.28x
Forward P/E
9.48x
PEG Ratio
1.74x
P/B
2.20x
P/S
2.24x
P/FCF
5.60x
EV/EBITDA
5.18x
Shares Out
58.5M
Financials (TTM)
Revenue
$868.5M
Net Income
$158.7M
EBITDA
$255.0M
Free Cash Flow
$347.9M
Op Cash Flow
$348.2M
EPS Basic
$2.76
EPS Diluted
$2.71
EPS Forward
$3.51
Gross Margin
77.2%
Op Margin
24.0%
Net Margin
18.3%
Balance Sheet
Total Assets
$1.27B
Total Liab.
$401.4M
Total Equity
$870.2M
Cash
$775.3M
LT Debt
$148.2M
Book Value/Sh
$15.14
Debt/Equity
0.28x
Current Ratio
3.60
Quick Ratio
3.58
Returns & Growth
ROE
18.2%
ROA
12.5%
ROIC
13.9%
Rev Growth YoY
+21.5%
EPS Growth YoY
+7.8%
Price Returns
2W
+2.7%
1M
+1.1%
3M
+10.7%
6M
-10.5%
12M
-8.4%
Technicals
52W High
$40.51
52W Low
$25.90
50d MA
$31.46
200d MA
$32.29
RSI (14)
59.00
ATR (14)
$1.14
Beta
0.89
Avg Volume
821K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$46.80
High
$62.00
Low
$31.00
Median
$46.00
Data updated apr 25, 2026 2:02pm
· Source: financialmodelingprep.com